Holen Sie sich die Stockscreener-App
97.55
6.17%
5.67
Handel nachbörslich:
97.55
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Yahoo Finance
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance UK
UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Analyst Ratings For Blueprint Medicines - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat
Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales - Investing.com
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Blueprint Medicines (BPMC) Scheduled to Post Earnings on Wednesday - MarketBeat
SG Americas Securities LLC Has $233,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Financial Times
Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know - Yahoo Finance
Blueprint Medicines Corp [NASDAQ: BPMC] Sees Decrease in Stock Value - Knox Daily
Activin Receptor Type 1 Market Review: All Eyes on 2024 Outlook - IndiaPolitics.com
The Blueprint Medicines Corp (BPMC) had a good session last reading, didn’t it? - US Post News
Brokers Issue Forecasts for Blueprint Medicines Co.'s Q2 2026 Earnings (NASDAQ:BPMC) - MarketBeat
Dimensional Fund Advisors LP Sells 16,619 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corp [BPMC] Stock sold by Insider Namouni Fouad for $0.32 million - Knox Daily
Holdings of Blueprint Medicines Corp (BPMC) are aligned with the stars - SETE News
Clearbridge Investments LLC Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines executive sells over $324k in stock By Investing.com - Investing.com Australia
Blueprint Medicines executive sells over $324k in stock - Investing.com India
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Fouad Namouni Sells 3,633 Shares - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Dana Investment Advisors Inc. - Defense World
Blueprint Medicines Corp [BPMC] Records 200-Day SMA of $94.83 - Knox Daily
Is Blueprint Medicines Corp (BPMC) a good investment opportunity? - US Post News
AQR Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Investors in cash trouble should check out Blueprint Medicines Corp (BPMC) - SETE News
Bank of Montreal Can Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
An Analysis of Blueprint Medicines Corp (BPMC)’s Potential Price Growth - Knox Daily
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Update - MarketBeat
9,964 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Acquired by Hsbc Holdings PLC - MarketBeat
Susquehanna Portfolio Strategies LLC Sells 57,540 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Wall Street SWOT: Blueprint Medicines stock rides Ayvakit wave amid pipeline promise - Investing.com
Analysts Set Blueprint Medicines Co. (NASDAQ:BPMC) Price Target at $120.00 - MarketBeat
Fred Alger Management LLC Buys 31,675 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Point72 Europe London LLP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Its Stock Has Paid Off Big Time For Blueprint Medicines Corp - SETE News
Integral Health Asset Management LLC Buys 130,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Can you now get a good deal on Blueprint Medicines Corp’s shares? - US Post News
Q2 2026 Earnings Estimate for Blueprint Medicines Co. (NASDAQ:BPMC) Issued By Zacks Research - MarketBeat
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):